Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Investing Activities (2023 - 2025)

Immunome (IMNM) has disclosed Cash from Investing Activities for 3 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 140.98% year-over-year to -$4.0 million, compared with a TTM value of $60.8 million through Dec 2025, up 171.48%, and an annual FY2025 reading of $60.8 million, up 171.48% over the prior year.
  • Cash from Investing Activities was -$4.0 million for Q4 2025 at Immunome, down from $123.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $123.9 million in Q3 2025 and bottomed at -$81.7 million in Q2 2024.
  • Average Cash from Investing Activities over 3 years is -$4.6 million, with a median of -$223000.0 recorded in 2023.
  • Peak annual rise in Cash from Investing Activities hit 67038.89% in 2024, while the deepest fall reached 35023.58% in 2024.
  • Year by year, Cash from Investing Activities stood at -$30.0 million in 2023, then soared by 132.52% to $9.8 million in 2024, then plummeted by 140.98% to -$4.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for IMNM at -$4.0 million in Q4 2025, $123.9 million in Q3 2025, and -$64.2 million in Q2 2025.